Chronic Hand Eczema (CHE) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Chronic Hand Eczema (CHE) is defined as either a long-term, relapsing course of HE or HE that is unresponsive to standard treatment with emollients and topical corticosteroids for more than three months or recurrence of symptoms twice within a year despite treatment. Clinical signs and symptoms of Chronic Hand Eczema comprise classic features of eczema localized to the hands and fingers, including dryness, erythema, edema, hyperkeratosis, scaling, lichenification, vesiculation/ blistering, fissures, pruritus, and pain. Eczema and dermatitis are used as synonyms. Both terms are used interchangeably to describe a particular type of inflammatory disorder of the skin that targets the epidermis and the dermis. Acute and subacute HE can be defined as eczema, localized to the hands, that lasts for less than three months and does not occur more than once per year. In the acute stage, vesicles will be present in most cases, although not always in irritant HE. Erythema, representing inflammation, is pronounced in acute HE, as is edema. A subjective sensation of burning and itching is present in most cases. Chronic HE refers to an eczematous process that lasts for more than three months or relapses twice or more often per year. Scaling and fissures are found in most cases. Hyperkeratosis is present in chronic irritant and allergic HE but is also found in the endogenous hyperkeratotic HE and other chronic patients.

 

The prevalence of Chronic Hand Eczema (CHE) varies from 540 to 629 per 100,000 population in the USA.

 

The competitive landscape of Chronic Hand Eczema (CHE) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Chronic Hand Eczema (CHE) across the 8 MM market from the center of Excellence/ Public/ Private hospitals participated. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Chronic Hand Eczema (CHE) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Chronic Hand Eczema (CHE) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Delgocitinib       LEO Pharma     Phase 3

2          Ruxolitinib         Incyte Corporation         Phase 2

3          ARQ-252          Arcutis Biotherapeutics, Inc.       Phase 2

4          alitretinoin         Stiefel, a GSK Company            Phase 3

5          ASN002            Asana BioSciences        Phase 2

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more